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HIV-specific cytotoxic T lymphocyte (CTL) responses
mediated by human leukocyte antigen (HLA) recognition
and antiretroviral drugs exert selection pressure on HIV-
1 in vivo. The selection of CTL escape mutations strongly
underpins the failure of CTL control in most untreated
infections whilst drug-resistance mutations predict
failure of drug control. These two evolutionary forces
share common target residues in HIV-1 at which their
selection effects could be synergistic or antagonistic,
such that the propensity to develop drug resistance and
virological treatment failure may be influenced by HLA
type. We examined HIV-1 reverse transcriptase (RT) and
protease sequences in a large clinical observational
cohort of 487 HIV-infected individuals and found
evidence of site-specific interactions between specific
antiretroviral drug exposures, HLA alleles and HIV
sequence diversity at population level. Such interactions
may have general and specific implications for explaining
in vivo/in vitro discordance of drug resistance, host-
specific susceptibility to drug resistance, individualiza-
tion of therapy and therapeutic vaccine design.
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We have previously presented evidence that viral
escape or adaptation to polymorphic human leukocyte
antigen (HLA) class I alleles accounts in large part for
the sequence diversity of HIV-1 [1]. Antiretroviral
drugs represent a relatively new evolutionary force, but
their characteristic primary selection effects are well
characterized [2]. In this study, we examined the sites
at which these two selective forces intersect in vivo to
shape HIV diversity at a population level.
Methods
Statistical methods
All analyses used the Epipop program as previously
described [1]. The population consensus sequence for
HIV-1 RT (20–227) and protease (1–99), with stan-
dard HXB2 numbering and alignment, was used as the
reference sequence in multivariate models. Power
calculations were conducted to limit analyses to only
those positions, drugs and HLA alleles for which 
there was at least 30% power to detect associations
with OR >2 (positive associations) or <0.5 (negative
associations) with P<0.05. Individual covariates were
then assessed for univariate association with mutation/
substitution, and discarded if P>0.1 and then subjected
to forward selection and backwards elimination 
procedures. Exact P values were determined for each
association.
HLA genotyping
All HLA-A and -B broad alleles were typed by a micro-
cytotoxicity assay using standard NIH techniques.
HIV-1 RT and protease sequencing
HIV-1 RNA was extracted from plasma samples  with
a QIAMP viral load RNA mini spin kit (Qiagen Inc,
Valencia, CA, USA) and cDNA for both HIV-1 protease
gene and codons 20–227 of RT was amplified using RT-
PCR (PCR kit; Life Technologies, Gaithersburg, MD,
USA). Individual second-round PCR reactions were
performed to amplify RT and protease. PCR products
were purified using Bresatec purification columns
(Bresatec, Adelaide, Australia) and sequenced in both
forward and reverse directions with a 373 ABI DNA
Sequencer (Applied Biosystems, Foster City, CA, USA).
Raw sequence was manually edited using software
packages Factura and MT Navigator (PE Applied
Biosystems, Foster City, CA, USA).
Results
In vivo selection of known antiretroviral drug-
resistance mutations in HIV-1 reverse transcriptase
(RT) and protease is evident at population level
We studied a total of 487 individuals in the predomi-
nantly clade B infected Western Australian HIV Cohort
[3]. Individuals generally had HIV-1 RT (positions
Background
20–227) and/or full-length protease sequencing under-
taken prior to initiation of antiretroviral therapy and
during virological failure as part of routine clinical
management. All analyses using multivariate logistic
regression models (with outcome as amino acid substi-
tution at single positions, HLAs and/or drugs as covari-
ates) were designed to reflect the biological dynamic of
competing or interacting selective pressures in vivo
acting to drive or constrain mutation at single viral
residues, as previously described [1]. In 220 individuals
with pre-treatment RT sequences available, the mean
frequency of nucleoside RT inhibitor (NRTI)- or non-
nucleoside RT inhibitor (NNRTI)-associated resistance
mutations (specifically RT M41L, E44D, A62V, K65R,
K70R, L74V, V75I, F77L, L100I, K103N, V118I,
Y181C, L210W, T215Y/F, K219Q and P225H) was
0.95% (range 0.5–3%). Protease inhibitor (PI)-associ-
ated resistance mutations (protease L10I/R/V, K20M,
L33F, M36I, G48V, A71V/T, V77I and V82A/F/T)
were present in 5.5% (range 0.6–33.1%) of 157 pre-
treatment protease sequences. Notably, M36I, V77I,
L10I/R/V and K20M were present in 33.1%, 26.1%,
12.3% and 7.6% of pre-treatment sequences, respec-
tively, and all other mutations in less than 1.9%. 
For the subset of 166 individuals with known serocon-
version dates, the mean time from seroconversion to
time of their first pre-treatment sequence was 1298
days.
The most recent RT and protease sequences of the
whole cohort (n=487) were then examined. Of these
individuals, 329 had either past or current treatment
with antiretroviral drugs at the time of viral sequencing.
NRTI- and NNRTI-associated mutations were detected
in these sequences with mean frequencies of 5.2% (range
0.2–20.2%) and 8.1% (range 0.3–29.8%) for PI muta-
tions. As the biological links between these 
mutations (particularly primary changes) and particular
antiretroviral drugs are well characterised in the 
literature [2], these serve as clear a priori hypotheses 
for drug/mutation associations to be tested in our popu-
lation dataset. We therefore examined only univariate
associations between the presence of mutations and
exposure to drugs known to induce these changes. 
All the associations that were significant are shown in
Table 1. 
Many of the ‘expected’ associations were detected
and had a high degree of statistical strength. For
example, the association between 3TC and RT M184V
had an odds ratio (OR) of >100 and P<0.0001. Notably,
RT L74V, which is uniquely induced by didanosine,
zalcitabine and abacavir and not other NRTIs, had
significant associations with only these three NRTIs. All
but one [saquinavir (SQV) and G48V] of the expected
associations between individual PIs and primary PI resis-
tance mutations were evident. Notably, G48V has been
reported most frequently in vivo in patients taking high-
dose SQV monotherapy, which has almost never been
used in this study cohort. The failure to detect all
expected associations was related to inadequate statis-
tical power in the case of RT K65R, V75I, V108I,
Q151M and P225H, which were rarely present and for
the drugs delavirdine, tenofovir, amprenavir, atazanivir
and lopinavir, to which there was low cumulative expo-
sure during the period studied.
HLA-driven selection in HIV-1 RT and protease
sequences is evident at population level
The population consensus amino acid for each position
in HIV-1 RT and protease was determined and
compared against the amino acids present in each indi-
vidual’s autologous (most recent) viral sequence at the
corresponding position. For each position, a multi-
variate analysis was carried out in which the outcome of
interest was presence of a substitution of consensus
amino acid;  the antiretroviral drugs used by the indi-
viduals as well as their HLA-A and -B (broad) serotypes
were included as covariates. At those positions that
were known primary or secondary drug-resistance
mutation sites, the characteristic drug-resistance amino
acid substitution was specified as the outcome (for
example, RT M184V). At all other positions, any non-
consensus amino acid was the outcome (for example,
RT I135x). 
As previously described, model selection steps were
carried out and multivariate P values <0.05 for indi-
vidual associations were considered significant. In HIV-
1 RT, significant positive (OR>2) and negative
(OR<0.5) HLA associations as reported in our previous
study were confirmed and are not reiterated here [1].
Negative associations (OR<0.5) are those in which the
HLA allele was associated with the presence of
consensus amino acid rather than variation from
consensus, in keeping with an adaptive change fixed in
consensus sequence. There were 43 statistically signifi-
cant HLA allele-specific polymorphisms detected in
protease, including strong ‘clustered’ polymorphisms
associated with HLA-B5 (T12S, K14R), HLA-A9
(Q18H, L19I), HLA-B12 (D35E, N37S), HLA-A1
[R41 (negative association), K43R], HLA-B15 (K43R,
M46I and I62V, P63P, A71T, V77I) and HLA-A3
(V77I, V82A, L90M). Few CTL epitopes have been
mapped in protease and the relatively high degree of
polymorphism in this protein may mitigate against
epitope mapping methods reliant on ex vivo responses
to consensus peptides. Notably the strong HLA associ-
ations across RT and protease are not abrogated by
inclusion of drug treatment as covariates in the models,
suggesting that these HLA alleles exert an independent
selective pressure on HIV sequence, including in the
face of drug treatment. 
M John et al.
© 2005 International Medical Press552
HLA-driven selection at drug-resistance sites as
evidence of possible CTL and drug interactions 
The multivariate models identified five sites in RT and
four sites in protease at which HLA alleles indepen-
dently increased the probability of a substitution
known also to predict resistance to one or more anti-
retroviral drugs (Table 2). In RT, positive HLA associ-
ations were found with the NRTI-associated mutations
(NAMS) M41L, D67N, K70R, V118I, L210W and
T215Y/F, which encode cross-resistance across the
NRTI class. For example, the odds of RT M41L was
increased in HLA-B7 individuals compared with all
other HLA-A and -B alleles (OR=2, P=0.019). In
protease, positive HLA associations were with
K20M/R, V32I, M36I and G48V. To examine these
interactions in further detail, an analysis was restricted
to only individuals in the total cohort who were being
treated with the relevant drug at the time of RT
sequencing. In those taking zidovudine (ZDV) (n=256),
32.8% of those with HLA-B7 developed M41L
compared with 20.3% of those without HLA-B7 [rela-
tive risk (RR)=1.9, P=0.033, Fisher’s exact test].
Similarly, 50% of HLA-A10s developed K70R
compared with 24% of those without HLA-A10
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Interactions between drugs and HLA
NRTI and NNRTI-associated
drug-resistance mutations Drug P value OR
M41L ABC <0.0001 4
ZDV <0.0001 17
E44D 3TC 0.001 >100
D67N ABC 0.031 2
ZDV <0.0001 >100
T69D ABC 0.011 5
ddC <0.0001 18
K70R ABC 0.019 2
ZDV <0.0001 13
d4T <0.0001 3
L74V ABC 0.033 3.79
ddC 0.002 7
ddI <0.0001 23
K103N EFV <0.0001 16
NVP <0.0001 9
V106A NVP 0.046 >100
V118I 3TC 0.021 3
3TC 0.021 3
Y181C NVP <0.0001 50
M184V ABC <0.0001 4
3TC <0.0001 >100
ddC <0.0001 4
ddI <0.0001 5
Y188L EFV 0.072 >100
G190A EFV <0.0001 12
NVP <0.0001 18
L210W ABC 0.006 3
ZDV 0.001 4
T215Y/F ABC 0.004 2
ZDV <0.0001 12
d4T <0.0001 5
K219Q ABC 0.028 2
ZDV <0.0001 18
PI-associated drug-
resistance mutations Drug P value OR
L10I/R/V IDV 0.006 2
NFV 0.018 2
SQV 0.001 3
D30N NFV 0.001 19
V32I RTV 0.024 13
L33F RTV 0.052 6
IDV 0.001 7
NFV 0.004 4
RTV 0.005 5
I54V IDV <0.0001 >100
RTV 0.027 4
SQV 0.025 4
A71T IDV 0.006 2
NFV 0.002 2
RTV <0.0001 4
SQV <0.0001 3
G73S/A IDV 0.009 7
SQV <0.0001 19
V77I RTV 0.019 2
V82A IDV 0.003 5
RTV 0.020 4
I84V IDV <0.0001 >100
RTV <0.0001 16
SQV <0.0001 38
N88D/S NFV <0.0001 21
L90M IDV <0.0001 5
NFV <0.0001 6
RTV <0.0001 8
SQV <0.0001 12
Table 1. Drug-resistance mutation at population level: the associations between known drug-resistance mutations in (A) HIV-1
RT and (B) protease, and the drugs used by individuals in the cohort
OR, odds ratio; PI, protease inhibitor; RT, reverse transcriptase; 3TC, lamivudine, d4T, stavudine; ddC, zalcitabine; ddI, didanosine; ABC, abacavir; EFV, efavirenz;
IDV, indinavir; NFV, nelfinavir; NVP, nevirapine; RTV, ritonivir, SQV, saquinavir; ZDV, zidovudine.
(A) (B)
(RR=3.1, P=0.002, Fisher’s exact test). The other
significant HLA–drug resistance interactions in individ-
uals ‘on-drugs’ in the cohort are shown in Table 2.
HLA-B13 reduced the odds of ZDV associated RT
T215Y/F. Negative HLA associations in protease were
at M36I (HLA-B8, OR=0.47, P=0.02), V77I (HLA-A3,
OR=0.5, P=0.02) and L90M (HLA-B40, OR=0.2,
P=0.04), suggesting that these HLA alleles could antag-
onize drug selection pressure at these sites. 
Discussion
HIV-specific CTLs may be considered analogous to
‘natural’ or endogenous antiviral drugs in that their
suppressive effect on HIV-1 is directed at specified
target residues within whole viral proteins (linear
epitopes) and critical changes affecting these sites abro-
gate the CTL response [4]. The selection effects of CTL
responses are uniquely configured by highly polymor-
phic HLA types that have evolved over millenia and
perennially influence HIV evolution from acute infec-
tion in individuals and imprint viral diversity across
large populations [1]. The short period in primary infec-
tion before the acute CTL response results in a tendency
for outgrowth of ‘most fit’ viral forms and some rever-
sion of adaptive changes made in previous host(s),
depending on the relative fitness in the new host and
genetic hurdles to reversion. The conditions favouring
drug-resistance mutations and their reversion are more
readily studied as drugs are a new exogenous evolu-
tionary force selecting a relatively small set of distinct
(primary) mutational signatures. For example, the rela-
tively high prevalence of M36I and V77I in pre-treat-
ment protease sequences may suggest a lesser fitness
cost in vivo and lack of early reversions. Drug exposure
can be controlled and the effects of single agents alone
can be examined in vitro. In contrast, exposure to HLA
cannot be controlled and the multiplicity of effects
related to multiple HLA types on multiple epitopes in
vivo is more difficult to fully characterize by laboratory-
based techniques. The population-based approach used
here offers a systematic method to observe complex
interacting immune and drug selection effects in vivo,
operating in a real population at the level of single viral
residues. 
General, non-site-specific interactions between
antiviral immune and drug responses have been
suggested to contribute to the control of drug-resistant
viraemia in treated patients [5] and discordant immuno-
logical response to therapy in those with virological
failure [6]. We have found that the selective imprints of
CTL responses are evident in post-treatment HIV-1 RT
and protease sequences and there are several sites at
which drugs also exert selective pressure (Table 2). It is
possible that some variable aspects of drug resistance
could be explained by such interactions, such as discor-
dance between in vitro and in vivo genotypic resistance
patterns, variable rates of emergence of drug-resistance
mutations not explained by drug dosing, plasma drug
levels and adherence, and alternative mutational path-
ways in different individuals. These observations imply
that there are factors other than those related to the
drugs alone and specific to individual hosts, such as
HLA, that may condition HIV sequence variation in
vivo in drug-treated individuals. As varying ancestral
and contemporary infectious environments worldwide
have shaped the non-random distribution of HLA
alleles in different ethnically or racially distinct HIV-
infected populations, the interactions between HLA and
drug pressure may be epidemic-specific. It is therefore
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Table 2. The interactions between HLA and drug selection effects in HIV-1 RT: sites of drug-resistance mutation where HLA
associations are found in multivariate models
Restrict to those taking the drug
Drug-resistance MV OR % with HLA allele % without HLA allele P value Fisher’s
Protein mutation HLA Drug for HLA n with mutant with mutant OR exact test
RT M41L B07 ZDV 2.3 256 32.8 20.3 1.9 0.033
D67N B15 ZDV 2.2 295 27.1 15.3 2.1 0.029
K70R A10 ZDV 3.1 294 50.0 24.0 3.1 0.002
V118I B15 3TC 5.0 256 14.9 4.8 3.5 0.020
L210W B08 ABC 3.1 77 35.0 12.3 3.7 0.031
L210W B08 ZDV 3.1 291 23.2 9.5 2.9 0.004
T215Y/F B07 ZDV 2.5 291 44.3 25.8 2.3 0.003
T215Y/F B07 d4T 2.5 179 50.0 32.8 2.3 0.015
T215Y/F B13 ZDV 0.1 291 11.1 31.5 0.3 0.050
Analysis restricted to only those taking drug at time of sequencing the specified drug-resistance mutation. HLA, human leukocyte antigen; MV OR, odds ratio in
multivariate models. 3TC, lamivudine, ABC, abacavir; d4T, stavudine; ZDV, zidovudine.
possible that in those developing countries that have
only recent access to antiretroviral therapy, the resis-
tance rate, typical resistance pathways and virological
efficacy of certain drugs differ from those characterized
in the predominantly western countries where most
drug development and testing has occurred. 
Other types of specific interactions have been
described, including the creation of a new (HLA-A2)
CTL epitope by M184V [7], the abrogation of an
HLA-A2 CTL response ex vivo by V82A [8], and
several patterns of persistent or enhanced CTL recog-
nition of drug-resistance mutations [9,10], including
when mutations were not fixed in autologous virus
species [10]. In the latter case, if an enhanced CTL
response actually drives reversion to wild-type in vivo,
an antagonistic (negative) HLA association may be
observed at a population level. Aside from interactions
at primary drug-resistance sites, drugs may also influ-
ence, through secondary, linked or compensatory
effects, CTL escape mutations selected post-treatment.
Apparent persistence or reversions of CTL escape
mutations (on mutational pathways constrained by
codon usage11) following drug treatment may thus be
driven by the drugs themselves, even without signifi-
cant changes to CTL responses.
The complexity of sequential multiple drug expo-
sures and variable time intervals between drug expo-
sure and sequencing is difficult to avoid in the study of
an observational cohort, nevertheless this tends to act
as a conservative bias in which selection effects may be
missed. The exact mechanism of HLA–drug interaction
in relation to the course of CTL magnitude over time
on treatment and degree of viral load suppression
cannot be fully elucidated here. However, the strong
positive associations we do find provide a number of
testable hypotheses regarding specific HLA–drug inter-
actions in vivo that should be further explored and
confirmed in a prospective manner in this and other
study populations. A better understanding of specific
HLA–drug interactions, especially the strongly antago-
nistic interactions with common population HLA
alleles may be exploited for better population tailored
treatment strategies and design of therapeutic vaccines
to prevent or delay the emergence of drug resistance.
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